| Citation: |
CUI Hanshu, LIU Bin. Controversy About Management of Osteoarthritis with Disease-modifying Anti-rheumatic Drugs[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 13-18. DOI: 10.12290/xhyxzz.2024-0802
|
Osteoarthritis (OA) is a degenerative joint cartilage disease characterized pathologically by osteophytes formation and subchondral bone damage. It leads to pain, stiffness, deformation and even disability in the patients, and increases the risk of comorbidities. As its pathophysiological mechanisms are not well understood, it is hard to identify the specific targets of OA and standardize its pharmacological treatments. Some scholars believe that synovial inflammation is the main factor of pain and progression of OA, so disease-modifying anti-rheumatic drugs (DMARDs) for inflammatory arthritis could be used to treat OA. However, others hold opposing views, arguing that inflammation is not the core driving factor of OA, and the available research results are not sufficient to support the application of DMARDs in OA. In addition, the side effects and monitoring requirements limit the application value of DMARDs in treatment of OA, especially for elderly OA patients with comorbidities. This article analyzes and discusses this debate based on the mechanisms of OA inflammation and pain, and in conjunction with relevant research findings from domestic and international studies.
| [1] |
Bijlsma J W J, Berenbaum F, Lafeber F P J G. Osteoarthritis: an update with relevance for clinical practice[J]. Lancet, 2011, 377(9783): 2115-2126. DOI: 10.1016/S0140-6736(11)60243-2
|
| [2] |
Bedenbaugh A V, Bonafede M, Marchlewicz E H, et al. Real-world health care resource utilization and costs among US patients with knee osteoarthritis compared with controls[J]. Clinicoecon Outcomes Res, 2021, 13: 421-435. DOI: 10.2147/CEOR.S302289
|
| [3] |
薛庆云, 王坤正, 裴福兴, 等. 中国40岁以上人群原发性骨关节炎患病状况调查[J]. 中华骨科杂志, 2015, 35(12): 1206-1212. DOI: 10.3760/cma.j.issn.0253-2352.2015.12.005
Xue Q Y, Wang K Z, Pei F X, et al. The survey of the prevalence of primary osteoarthritis in the population aged 40 years and over in China[J]. Chin J Orthop, 2015, 35(12): 1206-1212. DOI: 10.3760/cma.j.issn.0253-2352.2015.12.005
|
| [4] |
Lohan C, Coates G, Clewes P, et al. Estimating the cost and epidemiology of mild to severe chronic pain associated with osteoarthritis in England: a retrospective analysis of linked primary and secondary care data[J]. BMJ Open, 2023, 13(11): e073096. DOI: 10.1136/bmjopen-2023-073096
|
| [5] |
Hochberg M C, Altman R D, April K T, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee[J]. Arthritis Care Res (Hoboken), 2012, 64(4): 465-474. DOI: 10.1002/acr.21596
|
| [6] |
赵彦萍, 林志国, 林书典, 等. 骨关节炎诊疗规范[J]. 中华内科杂志, 2022, 61(10): 1136-1143. DOI: 10.3760/cma.j.cn112138-20220416-00280
Zhao Y P, Lin Z G, Lin S D, et al. Recommendations on the diagnosis and treatment of osteoarthritis in China[J]. Chin J Intern Med, 2022, 61(10): 1136-1143. DOI: 10.3760/cma.j.cn112138-20220416-00280
|
| [7] |
Leopoldino A O, Machado G C, Ferreira P H, et al. Paracetamol versus placebo for knee and hip osteoarthritis[J]. Cochrane Database Syst Rev, 2019, 2019(2): CD013273.
|
| [8] |
Zeng C, Dubreuil M, LaRochelle M R, et al. Association of tramadol with all-cause mortality among patients with osteoarthritis[J]. JAMA, 2019, 321(10): 969-982. DOI: 10.1001/jama.2019.1347
|
| [9] |
McNeill R, Boland J W, Wilcock A, et al. Non-steroidal anti-inflammatory drugs for pain in hospice/palliative care: an international pharmacovigilance study[J]. BMJ Support Palliat Care, 2024, 13(e3): e1249-e1257.
|
| [10] |
Bensa A, Salerno M, Boffa A, et al. Corticosteroid injections for the treatment of osteoarthritis present a wide spectrum of effects ranging from detrimental to disease-modifying: a systematic review of preclinical evidence by the ESSKA Orthobiologic Initiative[J]. Knee Surg Sports Traumatol Arthrosc, 2024, 32(11): 2725-2745. DOI: 10.1002/ksa.12242
|
| [11] |
Fu K, Robbins S R, McDougall J J. Osteoarthritis: the genesis of pain[J]. Rheumatology (Oxford), 2018, 57(S4): iv43-iv50.
|
| [12] |
Felson D T. Osteoarthritis as a disease of mechanics[J]. Osteoarthritis Cartilage, 2013, 21(1): 10-15. DOI: 10.1016/j.joca.2012.09.012
|
| [13] |
Roemer F W, Guermazi A, Hunter D J, et al. The association of meniscal damage with joint effusion in persons without radiographic osteoarthritis: the Framingham and MOST osteoarthritis studies[J]. Osteoarthritis Cartilage, 2009, 17(6): 748-753. DOI: 10.1016/j.joca.2008.09.013
|
| [14] |
Higuchi H, Shirakura K, Kimura M, et al. Changes in biochemical parameters after anterior cruciate ligament injury[J]. Int Orthop, 2006, 30(1): 43-47. DOI: 10.1007/s00264-005-0023-5
|
| [15] |
Ward B D, Furman B D, Huebner J L, et al. Absence of posttraumatic arthritis following intraarticular fracture in the MRL/MpJ mouse[J]. Arthritis Rheum, 2008, 58(3): 744-753. DOI: 10.1002/art.23288
|
| [16] |
Vlad S C, Neogi T, Aliabadi P, et al. No association between markers of inflammation and osteoarthritis of the hands and knees[J]. J Rheumatol, 2011, 38(8): 1665-1670. DOI: 10.3899/jrheum.100971
|
| [17] |
Myers S L, Brandt K D, O'Connor B L. Low dose prednis-one treatment does not reduce the severity of osteoarthritis in dogs after anterior cruciate ligament transection[J]. J Rheumatol, 1991, 18(12): 1856-1862.
|
| [18] |
Guermazi A, Neogi T, Katz J N, et al. Intra-articular corticosteroid injections for the treatment of hip and knee osteoarthritis-related pain: considerations and controversies with a focus on Imaging-Radiology Scientific Expert Panel[J]. Radiology, 2020, 297(3): 503-512. DOI: 10.1148/radiol.2020200771
|
| [19] |
Güngör Demir U, Demir A N, Toraman N F. Neuropathic pain in knee osteoarthritis[J]. Adv Rheumatol, 2021, 61(1): 67. DOI: 10.1186/s42358-021-00225-0
|
| [20] |
Wood M J, Miller R E, Malfait A M. The genesis of pain in osteoarthritis: inflammation as a mediator of osteoarthritis pain[J]. Clin Geriatr Med, 2022, 38(2): 221-238. DOI: 10.1016/j.cger.2021.11.013
|
| [21] |
Pan L Y, Nagib L, Ganguly S, et al. A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion[J]. Expert Opin Emerg Drugs, 2024, 29(4): 347-359. DOI: 10.1080/14728214.2024.2386174
|
| [22] |
Hermann W, Lambova S, Muller-Ladner U. Current treatment options for osteoarthritis[J]. Curr Rheumatol Rev, 2018, 14(2): 108-116. DOI: 10.2174/1573397113666170829155149
|
| [23] |
Smolen J S, Landewé R B M, Bergstra S A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update[J]. Ann Rheum Dis, 2023, 82(1): 3-18. DOI: 10.1136/ard-2022-223356
|
| [24] |
Abou-Raya A, Abou-Raya S, Khadrawe T. Retracted: methotrexate in the treatment of symptomatic knee osteoarthritis: randomised placebo-controlled trial[J]. Ann Rheum Dis, 2018, 77(7): e46. DOI: 10.1136/annrheumdis-2013-204856
|
| [25] |
Kingsbury S R, Tharmanathan P, Keding A, et al. Significant pain reduction with oral methotrexate in knee osteoarthritis; results from a randomised controlled phase Ⅲ trial of treatment effectiveness[abstract][J]. Arthritis Rheumatol, 2018, 70(S9): 428.
|
| [26] |
Kedor C, Detert J, Rau R, et al. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial[J]. RMD Open, 2021, 7(2): e001660. DOI: 10.1136/rmdopen-2021-001660
|
| [27] |
Kloppenburg M, Ramonda R, Bobacz K, et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2018, 77(12): 1757-1764. DOI: 10.1136/annrheumdis-2018-213202
|
| [28] |
Lechtenboehmer C A, Burkard T, Reichenbach S, et al. Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis[J]. Arthritis Res Ther, 2021, 23(1): 267. DOI: 10.1186/s13075-021-02654-0
|
| [29] |
Zhang W, Ouyang H W, Dass C R, et al. Current research on pharmacologic and regenerative therapies for osteoarthritis[J]. Bone Res, 2016, 4: 15040. DOI: 10.1038/boneres.2015.40
|
| [30] |
Persson M S M, Sarmanova A, Doherty M, et al. Comment on: conventional and biologic disease-modifying anti-rheu-matic drugs for osteoarthritis: a meta-analysis of randomized controlled trials[J]. Rheumatology (Oxford), 2018, 57(10): 1830-1837. DOI: 10.1093/rheumatology/key131
|
| [31] |
Ferrero S, Wittoek R, Allado E, et al. Methotrexate treat-ment in hand osteoarthritis refractory to usual treatments: a randomised, double-blind, placebo-controlled trial[J]. Semin Arthritis Rheum, 2021, 51(4): 831-838. DOI: 10.1016/j.semarthrit.2021.04.016
|
| [32] |
中国医师协会风湿免疫科医师分会骨关节炎学组. 中国膝骨关节炎临床药物治疗专家共识(2023)[J]. 中华内科杂志, 2024, 63(6): 560-578. DOI: 10.3760/cma.j.cn112138-20240402-00215
Osteoarthritis Group of the Rheumatology and Immunology Physicians Branch of the Chinese Medical Doctor Associa-tion. Consensus on clinical drug therapy for knee osteoarthritis in China (2023)[J]. Chin J Intern Med, 2024, 63(6): 560-578. DOI: 10.3760/cma.j.cn112138-20240402-00215
|
| [33] |
Mathieu S, Tournadre A, Soubrier M, et al. Effect of disease-modifying anti-rheumatic drugs in osteoarthritis: a meta-analysis[J]. Joint Bone Spine, 2022, 89(6): 105444. DOI: 10.1016/j.jbspin.2022.105444
|
| [34] |
Wittoek R, Verbruggen G, Vanhaverbeke T, et al. RANKL blockade for erosive hand osteoarthritis: a randomized placebo-controlled phase 2a trial[J]. Nat Med, 2024, 30(3): 829-836. DOI: 10.1038/s41591-024-02822-0
|
| [35] |
Salliot C, Van Der Heijde D. Long-term safety of metho-trexate monotherapy in patients with rheumatoid arthritis: a systematic literature research[J]. Ann Rheum Dis, 2009, 68(7): 1100-1104. DOI: 10.1136/ard.2008.093690
|
| [36] |
Freitas R, Godinho F, Madeira N, et al. Safety and effectiveness of biologic disease-modifying antirheumatic drugs in older patients with rheumatoid arthritis: a prospective cohort study[J]. Drugs Aging, 2020, 37(12): 899-907. DOI: 10.1007/s40266-020-00801-x
|
| [37] |
Bähler C, Huber C A, Brüngger B, et al. Multimorbidity, health care utilization and costs in an elderly community-dwelling population: a claims data based observational study[J]. BMC Health Serv Res, 2015, 15: 23. DOI: 10.1186/s12913-015-0698-2
|
| [38] |
Dell'Isola A, Vinblad J, Turkiewicz A, et al. The coexist-ence of diabetes, hypertension and obesity is associated with worse pain outcomes following exercise for osteoarthritis: a cohort study on 80, 893 patients[J]. Osteoarthritis Cartilage, 2024, 32(10): 1308-1318. DOI: 10.1016/j.joca.2024.05.005
|
| [39] |
Boshra M S, Ahmed A S, Salem H F, et al. Safety and efficacy of methotrexate monotherapy vs methotrexate plus leflunomide combination therapy in early active rheumatoid arthritis patients[J]. Med Sci, 2016, 5(1): 117-133. DOI: 10.5455/medscience.2015.04.8350
|
| [1] | ZHANG Song, QIU Luhong, LIU Yingxian, XU Xiqi. Interpretation of JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 320-327. DOI: 10.12290/xhyxzz.2023-0630 |
| [2] | Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, Gitelman Syndrome Consensus Working Group. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 902-912. DOI: 10.12290/xhyxzz.2021-0555 |
| [3] | WANG Shi-rui, CHEN Shi, ZHU Hui-juan. Evaluation and Treatment of Coronavirus Disease 2019 with Obesity[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 13-17. DOI: 10.12290/xhyxzz.20200244 |
| [4] | CAO Wei, LI Tai-sheng. Treatment of Coronavirus Disease 2019: Timing Determines Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 5-8. DOI: 10.3969/j.issn.1674-9081.2021.01.002 |
| [5] | An-li TONG, Han-zhong LI. Consensus and Controversy on the Treatment of Multiple Endocrine Neoplasia[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 365-369. DOI: 10.3969/j.issn.1674-9081.2020.04.002 |
| [6] | Nian-sheng YANG. Trends in the Pharmacological Treatment for Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 247-251. DOI: 10.3969/j.issn.1674-9081.20200061 |
| [7] | Chen-xi YU, Shui SUN. Roles of Long Noncoding RNAs in the Development and Progression of Osteoarthritis[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 85-90. DOI: 10.3969/j.issn.1674-9081.20170138 |
| [8] | Zhi-tong GE, Jian-chu LI. Application of Ultrasonic Intervention in the Treatment of Vascular Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 62-67. DOI: 10.3969/j.issn.1674-9081.20190210 |
| [9] | Yan KANG. Treatments of Sepsis and Septic Shock: Advancements in Controversy[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(5): 421-425. DOI: 10.3969/j.issn.1674-9081.2018.05.009 |
| [10] | Exper Group for Treatment of Breast Carcinoma in Eldly Chinese Patients. Consensus on the Treatment of Breast Carcinoma in Elderly Chinese Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(4): 307-312. DOI: 10.3969/j.issn.1674-9081.2018.04.005 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: